Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

"Conflict of interest and acknowledgments The authors declare no competing financial or otherwise conflicts of interest with respect to the content of this review. J.L. and T.V. are supported by research grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01 AI098771 and AI111965). J.L. and T.V. are also supported by the Australian National Health and Medical Research Council (NHMRC, APP1026109). H.K.C., Q.T.Z. and J.L. acknowledge the financial support from NHMRC Project Grant funding scheme (APP1065046). J.L. is an Australian NHMRC Senior Research Fellow. T.V. is an Australian NHMRC Industry Career Development Research Fellow. Q.T.Z. is an Australian NHMRC Early Career Research Fellow. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health."

"The authors declare no competing financial or otherwise conflicts of interest with respect to the content of this review. J.L. and T.V. are supported by research grants from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (R01 AI098771 and AI111965). J.L. and T.V. are also supported by the Australian National Health and Medical Research Council (NHMRC, APP1026109). H.K.C., Q.T.Z. and J.L. acknowledge the financial support from NHMRC Project Grant funding scheme (APP1065046). J.L. is an Australian NHMRC Senior Research Fellow. T.V. is an Australian NHMRC Industry Career Development Research Fellow. Q.T.Z. is an Australian NHMRC Early Career Research Fellow. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health."